Clinical and Translational Oncology

, Volume 12, Issue 1, pp 8–14

Molecular biology of therapy-related leukaemias

Educational Series

DOI: 10.1007/s12094-010-0460-5

Cite this article as:
Joannides, M. & Grimwade, D. Clin Transl Oncol (2010) 12: 8. doi:10.1007/s12094-010-0460-5


Therapy-related leukaemias are becoming an increasing healthcare problem as more patients survive their primary cancers. The nature of the causative agent has an important bearing upon the characteristics, biology, time to onset and prognosis of the resultant leukaemia. Agents targeting topoisomerase II induce acute leukaemias with balanced translocations that generally arise within 3 years, often involving the MLL, RUNX1 and RARA loci at 11q23, 21q22 and 17q21 respectively. Chromosomal breakpoints have been found to be preferential sites of topoisomerase II cleavage, which are believed to be repaired by the non-homologous end-joining DNA repair pathway to generate chimaeric oncoproteins that underlie the resultant leukaemias. Therapy-related acute myeloid leukaemias occurring after exposure to antimetabolites and/or alkylating agents are biologically distinct with a longer latency period, being characterised by more complex karyotypes and loss of p53. Although treatment of therapy-related leukaemias represents a considerable challenge due to prior therapy and comorbidities, curative therapy is possible, particularly in those with favourable karyotypic features.


TopoisomeraseTherapy-related AMLAlkylating agents

Copyright information

© Feseo 2010

Authors and Affiliations

  1. 1.Department of Medical & Molecular GeneticsKing’s College London School of MedicineLondonUK